ALNY Logo

Alnylam Pharmaceuticals, Inc. (ALNY) 

NASDAQ
Market Cap
$35.03B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
428 of 776
Rank in Industry
226 of 433

Largest Insider Buys in Sector

ALNY Stock Price History Chart

ALNY Stock Performance

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; …

Insider Activity of Alnylam Pharmaceuticals, Inc.

Over the last 12 months, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $51.14M worth of Alnylam Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $46.01M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 595,002 shares for transaction amount of $42.76M was made by Sanofi (10 percent owner) on 2017‑05‑31.

List of Insider Buy and Sell Transactions, Alnylam Pharmaceuticals, Inc.

2024-08-20SaleChief Executive Officer
15,000
0.0117%
$280.00$4.2M-2.58%
2024-08-12SaleCSO & EVP, Head of Research
22,025
0.0172%
$270.99$5.97M+1.38%
2024-08-06Saledirector
20,250
0.0157%
$262.00$5.31M+3.94%
2024-08-01SaleChief Executive Officer
15,148
0.012%
$270.00$4.09M+1.28%
2024-07-11SaleChief Executive Officer
7,093
0.006%
$261.00$1.85M0.00%
2024-06-25SaleChief Executive Officer
8,301
0.0063%
$230.99$1.92M+12.62%
2024-06-25SaleEVP, Chief Financial Officer
1,605
0.0012%
$231.00$370,747+12.62%
2024-06-25SaleCMO & EVP Dev & Med Affairs
2,103
0.0016%
$230.99$485,773+12.62%
2024-06-25SaleCSO & EVP, Head of Research
1,198
0.0009%
$230.99$276,731+12.62%
2024-06-25SaleEVP, Chief Commercial Officer
1,605
0.0012%
$231.00$370,747+12.62%
2024-06-25Saledirector
8,500
0.0067%
$240.00$2.04M+12.62%
2024-06-24Saledirector
32,450
0.0254%
$220.69$7.16M+21.32%
2024-05-29Saledirector
21,700
0.0173%
$148.60$3.22M+81.51%
2024-02-29Saledirector
30,000
0.0241%
$151.34$4.54M+3.53%
2024-02-28SaleChief Executive Officer
2,932
0.0023%
$155.31$455,357+0.65%
2024-02-28SaleEVP, Chief Financial Officer
574
0.0005%
$155.30$89,145+0.65%
2024-02-28SaleCMO & EVP Dev & Med Affairs
574
0.0005%
$155.30$89,145+0.65%
2024-02-28SaleEVP, Chief Commercial Officer
501
0.0004%
$155.30$77,805+0.65%
2024-02-28SaleEVP, CLO & Secretary
329
0.0003%
$155.30$51,095+0.65%
2024-02-16SaleChief Executive Officer
6,190
0.005%
$147.93$915,699+6.42%

Insider Historical Profitability

33.72%
BONNEY MICHAEL Wdirector
16029
0.0124%
$271.6222<0.0001%
PYOTT DAVID E Idirector
136
0.0001%
$271.6211+45.98%
SHARP PHILLIP Adirector
0
0%
$271.62214+68.46%
Sanofi10 percent owner
10554134
8.1827%
$271.6260+18.68%
NOVARTIS AG10 percent owner
4051002
3.1408%
$271.6231<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Capital World Investors$1.91B10.1112.79M-20.93%-$505.94M0.32
The Vanguard Group$1.79B9.4811.99M+0.42%+$7.53M0.03
Fidelity Investments$1.49B7.889.97M-3.34%-$51.46M0.1
BlackRock$1.35B7.149.03M+5.91%+$75.31M0.03
Wellington Management Company$1.08B5.77.21M-0.07%-$776,093.850.18
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.